248 related articles for article (PubMed ID: 9680348)
1. Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy.
Drach J; Ackermann J; Fritz E; Krömer E; Schuster R; Gisslinger H; DeSantis M; Zojer N; Fiegl M; Roka S; Schuster J; Heinz R; Ludwig H; Huber H
Blood; 1998 Aug; 92(3):802-9. PubMed ID: 9680348
[TBL] [Abstract][Full Text] [Related]
2. Predictive role of interphase cytogenetics for survival of patients with multiple myeloma.
Königsberg R; Zojer N; Ackermann J; Krömer E; Kittler H; Fritz E; Kaufmann H; Nösslinger T; Riedl L; Gisslinger H; Jäger U; Simonitsch I; Heinz R; Ludwig H; Huber H; Drach J
J Clin Oncol; 2000 Feb; 18(4):804-12. PubMed ID: 10673522
[TBL] [Abstract][Full Text] [Related]
3. Activating mutations of N- and K-ras in multiple myeloma show different clinical associations: analysis of the Eastern Cooperative Oncology Group Phase III Trial.
Liu P; Leong T; Quam L; Billadeau D; Kay NE; Greipp P; Kyle RA; Oken MM; Van Ness B
Blood; 1996 Oct; 88(7):2699-706. PubMed ID: 8839865
[TBL] [Abstract][Full Text] [Related]
4. Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p).
Avet-Loiseau H; Leleu X; Roussel M; Moreau P; Guerin-Charbonnel C; Caillot D; Marit G; Benboubker L; Voillat L; Mathiot C; Kolb B; Macro M; Campion L; Wetterwald M; Stoppa AM; Hulin C; Facon T; Attal M; Minvielle S; Harousseau JL
J Clin Oncol; 2010 Oct; 28(30):4630-4. PubMed ID: 20644101
[TBL] [Abstract][Full Text] [Related]
5. Comparison of vincristine, carmustine, melphalan, cyclophosphamide, prednisone (VBMCP) and interferon-alpha with melphalan and prednisone (MP) and interferon-alpha (IFN-alpha) in patients with good-prognosis multiple myeloma: a prospective randomized study. Greek Myeloma Study Group.
Zervas K; Pouli A; Gregoraki B; Anagnostopoulos N; Dimopoulos MA; Bourantas K; Tzilianos M; Barbarousi D; Venetis E; Vyniou N; Maniatis A
Eur J Haematol; 2001 Jan; 66(1):18-23. PubMed ID: 11168503
[TBL] [Abstract][Full Text] [Related]
6. Correlation between burden of 17P13.1 alteration and rapid escape to plasma cell leukaemia in multiple myeloma.
Mangiacavalli S; Pochintesta L; Cocito F; Pompa A; Bernasconi P; Cazzola M; Corso A
Br J Haematol; 2013 Aug; 162(4):555-8. PubMed ID: 23718846
[No Abstract] [Full Text] [Related]
7. Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization.
Zojer N; Königsberg R; Ackermann J; Fritz E; Dallinger S; Krömer E; Kaufmann H; Riedl L; Gisslinger H; Schreiber S; Heinz R; Ludwig H; Huber H; Drach J
Blood; 2000 Mar; 95(6):1925-30. PubMed ID: 10706856
[TBL] [Abstract][Full Text] [Related]
8. Early harvest and late transplantation as an effective therapeutic strategy in multiple myeloma.
Gertz MA; Lacy MQ; Inwards DJ; Chen MG; Pineda AA; Gastineau DA; Greipp PR; Lust JA; Tefferi A; Witzig TE; Kyle RA; Litzow MR
Bone Marrow Transplant; 1999 Feb; 23(3):221-6. PubMed ID: 10084252
[TBL] [Abstract][Full Text] [Related]
9. Additional genetic abnormalities significantly worsen poor prognosis associated with 1q21 amplification in multiple myeloma patients.
Grzasko N; Hus M; Pluta A; Jurczyszyn A; Walter-Croneck A; Morawska M; Chocholska S; Hajek R; Dmoszynska A
Hematol Oncol; 2013 Mar; 31(1):41-8. PubMed ID: 22674819
[TBL] [Abstract][Full Text] [Related]
10. Interphase fluorescence in situ hybridization analysis of del(11)(q23) and del(17)(p13) in chronic lymphocytic leukemia. a study of 40 early-onset patients.
Doneda L; Montillo M; Intropido L; Tedeschi A; Morra E; Larizza L
Cancer Genet Cytogenet; 2003 Jan; 140(1):31-6. PubMed ID: 12550755
[TBL] [Abstract][Full Text] [Related]
11. The clinical impact and molecular biology of del(17p) in multiple myeloma treated with conventional or thalidomide-based therapy.
Boyd KD; Ross FM; Tapper WJ; Chiecchio L; Dagrada G; Konn ZJ; Gonzalez D; Walker BA; Hockley SL; Wardell CP; Gregory WM; Child JA; Jackson GH; Davies FE; Morgan GJ;
Genes Chromosomes Cancer; 2011 Oct; 50(10):765-74. PubMed ID: 21961181
[TBL] [Abstract][Full Text] [Related]
12. Increased conventional chemotherapy does not improve survival in multiple myeloma: long-term results of two PETHEMA trials including 914 patients.
Bladé J; San Miguel JF; Fontanillas M; Esteve J; Maldonado J; Alcalá A; Brunet S; García-Conde J; Besalduch J; Moro MJ; Fernández-Calvo J; Conde E; Font L; Gardella S; Carnero M; Carbonell F; Martí JM; Hernández-Martín J; Ortega F; Besses C; Ribera JM; Trujillo J; Escudero ML; Rozman C; Estapé J; Montserrat E
Hematol J; 2001; 2(4):272-8. PubMed ID: 11920260
[TBL] [Abstract][Full Text] [Related]
13. Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: a Southwest Oncology Group study.
Salmon SE; Crowley JJ; Grogan TM; Finley P; Pugh RP; Barlogie B
J Clin Oncol; 1994 Nov; 12(11):2405-14. PubMed ID: 7964957
[TBL] [Abstract][Full Text] [Related]
14. High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA.
Bladé J; Rosiñol L; Sureda A; Ribera JM; Díaz-Mediavilla J; García-Laraña J; Mateos MV; Palomera L; Fernández-Calvo J; Martí JM; Giraldo P; Carbonell F; Callís M; Trujillo J; Gardella S; Moro MJ; Barez A; Soler A; Font L; Fontanillas M; San Miguel J;
Blood; 2005 Dec; 106(12):3755-9. PubMed ID: 16105975
[TBL] [Abstract][Full Text] [Related]
15. p53 nuclear expression correlates with hemizygous TP53 deletion and predicts an adverse outcome for patients with relapsed/refractory multiple myeloma treated with lenalidomide.
Chen MH; Qi CX; Saha MN; Chang H
Am J Clin Pathol; 2012 Feb; 137(2):208-12. PubMed ID: 22261445
[TBL] [Abstract][Full Text] [Related]
16. Trisomy 12 and p53 deletion in chronic lymphocytic leukemia detected by fluorescence in situ hybridization: association with morphology and resistance to conventional chemotherapy.
Cano I; Martinez J; Quevedo E; Pinilla J; Martin-Recio A; Rodriguez A; Castañeda A; López R; Pérez-Piño T; Hernández-Navarro F
Cancer Genet Cytogenet; 1996 Sep; 90(2):118-24. PubMed ID: 8830719
[TBL] [Abstract][Full Text] [Related]
17. Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479.
Oken MM; Harrington DP; Abramson N; Kyle RA; Knospe W; Glick JH
Cancer; 1997 Apr; 79(8):1561-7. PubMed ID: 9118039
[TBL] [Abstract][Full Text] [Related]
18. The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486.
Oken MM; Leong T; Lenhard RE; Greipp PR; Kay NE; Van Ness B; Keimowitz RM; Kyle RA
Cancer; 1999 Sep; 86(6):957-68. PubMed ID: 10491521
[TBL] [Abstract][Full Text] [Related]
19. Complete remission induction with combined VBMCP chemotherapy and interferon (rIFN alpha 2b) in patients with multiple myeloma.
Oken MM; Kyle RA; Greipp PR; Kay NE; Tsiatis A; Gregory SA; Spiegel R J; O'Connell M J
Leuk Lymphoma; 1996 Feb; 20(5-6):447-52. PubMed ID: 8833401
[TBL] [Abstract][Full Text] [Related]
20. VAD-PECC regimen in the treatment of advanced-stage multiple myeloma.
Delain M; Linassier C; Petitdidier C; Goupille P; Luthier F; Combe M; Reisenleiter M; Benboubker L; Lamagnère JP; Colombat P
J Clin Oncol; 1994 Dec; 12(12):2706-13. PubMed ID: 7989948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]